Advertisement
Australia markets closed

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • AUD/USD

    0.6421
    -0.0004 (-0.07%)
     

  • OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD

    2,406.70
    +8.70 (+0.36%)
     

  • Bitcoin AUD

    99,704.09
    +4,035.16 (+4.22%)
     

  • CMC Crypto 200

    1,371.97
    +59.34 (+4.52%)
     

  • AUD/EUR

    0.6023
    -0.0008 (-0.13%)
     

  • AUD/NZD

    1.0893
    +0.0018 (+0.17%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,037.65
    -356.67 (-2.05%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • Dow Jones

    37,986.40
    +211.02 (+0.56%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Genenta to present at upcoming scientific congresses

Genenta Science
·2-min read

ASGCT – ASCO – EHA

MILAN, Italy and NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced it will be presenting at several upcoming scientific congresses in May and June.

Details of the presentations are as follows:

American Society of Cell and Gene Therapy (ASGCT) 24th Annual Meeting, May 11-14, virtual

Title: Changes in the Tumor Microenvironment in Patients with Glioblastoma Multiforme Treated with IFN-a Immune Cell & Gene Therapy (TEM-GBM_001 Study)
Type: Oral presentation
Time: Friday May 14, 1.30-1.45 PM CET

ADVERTISEMENT

2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8, virtual

Title: A phase I-IIa study of genetically modified Tie-2 expressing monocytes in patients with glioblastoma multiforme (TEM-GBM Study)
Type: Poster presentation
Day: June 4

European Hematology Association (EHA) 2021 Virtual Congress, June 9-17, virtual

Title: A Phase I-IIA Study of Genetically Modified TIE-2 Expressing Monocytes in Patients with Glioblastoma Multiforme (TEM-GBM Study)
Type: Oral presentation
Time: Sunday June 13, 7.45-8.30 PM CET

About Genenta Science

Genenta (www.genenta.com) is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes – TEMs). Temferon™, which is under investigation in a Phase I/IIa clinical trial in newly diagnosed Glioblastoma Multiforme patients, is not restricted to pre-selected tumor antigens nor type and has been designed to reach solid tumors, one of the main unresolved challenge in immuno-oncology. Based in Milan, Italy, and New York, USA, Genenta has raised more than €33.6 million (~$40 million) in three separate rounds of financing.

Investor Relator - LifeSci Advisors:

Genenta Media/Investor Contact:

GENENTA SCIENCE Srl

Mary-Ann Chang, CFA

Stefania Mazzoleni, PhD

OSR - DiBit 1 - Via Olgettina, 58 - 20132 Milan (Italy)

+44 7483 28.48.53

+39 339 709.59.31

LaunchLabs - Alexandria Center, 14th Floor

mchang@lifesciadvisors.com

stefania.mazzoleni@genenta.com

430 East 29th Street - New York, NY 10016 (USA)